- Conditions
- Anemia; Sickle-Cell, With Crisis, Acute Pain
- Interventions
- Ketamine, Pain management
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hemoglobin SC Disease
- Interventions
- Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid
- Drug · Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Acute Pain
- Interventions
- Virtual Reality Headset and Hand-Held Controllers, Blindfolding and Noise Cancelling
- Device · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Sickle Cell Crisis, Sickle Cell Disease
- Interventions
- Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Crizanlizumab, Placebo
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 11 more
- Conditions
- Sickle Cell Disease, Sickle Cell Crisis, Vaso-Occlusive Crises
- Interventions
- Comprehensive Care Plan
- Other
- Lead sponsor
- Valley Anesthesiology Consultants
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Inclacumab, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
- Conditions
- Anemia, Sickle Cell
- Interventions
- Nitric Oxide, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Oakland, California • Aurora, Colorado + 7 more
- Conditions
- Acute Vaso Occlusive Crisis (VOC)
- Interventions
- L-citrulline, D5 1/2NS
- Drug · Other
- Lead sponsor
- Asklepion Pharmaceuticals, LLC
- Industry
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Jackson, Mississippi
- Conditions
- Sickle Cell Disease
- Interventions
- Crizanlizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 100 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Augusta, Georgia + 3 more
- Conditions
- Sickle Cell Disease Vaso-occlusive Crisis
- Interventions
- CSL889, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 16
- States / cities
- Oakland, California • Orange, California • Fort Myers, Florida + 11 more
- Conditions
- Sickle Cell Disease, Sickle Cell Crisis
- Interventions
- Ketamine hydrochloride injection, Placebo
- Drug · Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Years to 24 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Brookline, Massachusetts
- Conditions
- Sickle Cell Disease, Thalassemia
- Interventions
- Etavopivat tablets
- Drug
- Lead sponsor
- Forma Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 14
- States / cities
- Cerritos, California • Los Angeles, California • Oakland, California + 9 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode
- Interventions
- L-citrulline, Placebo
- Drug · Other
- Lead sponsor
- Suvankar Majumdar
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
- Interventions
- Inclacumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 18
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
- Interventions
- Inclacumab, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis, Acute Chest Syndrome
- Interventions
- A-001, Placebo
- Drug · Other
- Lead sponsor
- Anthera Pharmaceuticals
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 3 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Varespladib, Placebo (Normal Saline)
- Drug · Other
- Lead sponsor
- Anthera Pharmaceuticals
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Sickle Cell Crisis
- Interventions
- Care pathway
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 5,328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Virtual Reality Therapy
- Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee
- Conditions
- Pain, Sickle Cell Disorder
- Interventions
- Normal saline, Ketamine
- Drug
- Lead sponsor
- Billy Sin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Sickle-Cell Disease With Crisis
- Interventions
- sublingual sufentanil
- Drug
- Lead sponsor
- Jason Wilson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Sickle Cell Disease
- Interventions
- sodium nitrite injection, usp
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 8 Years to 23 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Anemia, Sickle Cell
- Interventions
- Rivipansel, Placebo
- Drug · Other
- Lead sponsor
- Biossil Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 126
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more